Drugs & Therapy Perspectives

, Volume 20, Issue 4, pp 1–4 | Cite as

Adefovir dipivoxil: an effective treatment option for chronic hepatitis B

Drugs and Profile Reports
  • 18 Downloads

Keywords

Lamivudine Adefovir Adefovir Dipivoxil Lamivudine Resistance Differential Feature Table 

References

  1. 1.
    Dando TM, Plosker, GL. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63 (20): 2215–34.PubMedCrossRefGoogle Scholar
  2. 2.
    British National Formulary. No. 46. London: The Pharmaceutical Press, 2003 SepGoogle Scholar
  3. 3.
    Gilead Sciences Inc. Hepsera (adefovir dipivoxil) full prescribing information. Foster City (CA): Gilead Sciences Inc., 2002 SepGoogle Scholar
  4. 4.
    European Agency for Evaluation of Medicinal Products. Hepsera 10mg: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2003 Dec 5]
  5. 5.
    Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 Feb; 348 (9): 808–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 Feb; 348 (9): 800–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Hadziyannis S, Tassopoulos N, Heathcote J, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [oral presentation]. The 38th Annual Meeting of the European Association for the Study of the Liver; 2003 Mar 29–Apr 1; IstanbulGoogle Scholar
  8. 8.
    Hadziyannis S, Tassopoulos N, Heathcote J, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [abstract no. 492]. J Hepatol 2003 Apr; 38 Suppl. 2: 143CrossRefGoogle Scholar
  9. 9.
    Westland CE, Yang H, Delaney WE IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003 Jul; 38 (1): 96–103.PubMedCrossRefGoogle Scholar
  10. 10.
    Xiong S, Yang H, Westland CE, et al. Resistance surveillance of HBeAg- chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil [abstract]. J Hepatol 2003; 38 Suppl. 2: 182.CrossRefGoogle Scholar
  11. 11.
    Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis [abstract no. 845]. Hepatology 2002 Oct; 36 (Pt 2): 374AGoogle Scholar
  12. 12.
    Willems B, Lau G, Leung N, et al. Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine: 52-week results [abstract no. 45 plus poster]. Fourth International Workshop Therapies for Viral Hepatitis; 2002 Oct 29–31; BostonGoogle Scholar
  13. 13.
    Sung JJY, Lai JY, Zeuzem S, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis [abstract no. 69]. J Hepatol 2003 Apr; 38 Suppl. 2: 25CrossRefGoogle Scholar
  14. 14.
    Heathcote J, Chang T-T, Lim SG, et al. Safety profile of 48 weeks of adefovir dipivoxil (ADV) 10 mg for the treatment of chronic hepatitis B: an integrated analysis of two phase III studies [abstract no. 1882]. Hepatology 2002 Oct; 36 (Pt 2): 633AGoogle Scholar
  15. 15.
    Chang TT, Lim SG, Hadziyannis S, et al. Long-term safety of adefovir dipivoxil (ADV) 10mg once daily for chronic hepatitis B (CHB): an integrated analysis of two phase II studies [abstract no. 454]. J Hepatol 2003 Apr; 38 Suppl. 2: 133CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations